Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated a positive financial outlook, as evidenced by a projected acceleration in procedure volumes exceeding 50% year-over-year in the second half of 2026, driven by commercial initiatives. The company reported strong capital system placements, achieving 58 new systems, surpassing prior guidance, which signals robust demand despite a slightly softening macroeconomic environment. Additionally, Q3'25 financial results indicate sales of $83.3 million, reflecting a 43% year-over-year increase and exceeding both internal targets and consensus estimates, further highlighting the company's growth trajectory and strong market positioning.

Bears say

The financial outlook for PROCEPT BioRobotics is largely negative due to several concerning metrics reported in its recent financial disclosures. The company reported fourth quarter revenue that was 19% below consensus expectations and subsequently lowered its fiscal year 2026 sales guidance by 5%, resulting in a midpoint estimate that is significantly below analyst projections. Furthermore, the decline in handpiece sales, attributed to the elimination of bulk purchase discounts and inventory de-stocking, indicates operational challenges that may hinder future revenue growth.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.